This partnership underscores a shared commitment to expanding access to ATMPs for both Australian and International patients through clinical trials.

The MoU also affirms joint efforts to advance capabilities across Australia’s cell and gene therapy (CGT) sector – bolstering support for the growing global CGT market and driving innovation and manufacturing capacity for the Asia Pacific (APAC) region.

Stephen Thompson, VVMF CEO, said, “VVMF is proud to collaborate with Cell Therapies, Australia’s leading capability in cell therapy manufacturing. Our complementary strengths and services reinforce Australia’s unique biomanufacturing ecosystem and showcase why Australia is a premier destination for the development and production of cell and gene therapies. Together we are committed to improving outcomes for patients, customers, and partners across Australia, the APAC region, and globally”